• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Genetic Testing in Depression

Genetic Testing in Depression

September 10, 2021
Thomas Jordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD. Dr. Jordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Perlis RH et al, Depress Anxiety 2020;37(9):834–841

STUDY TYPE: Randomized controlled trial

By tailoring medications to a patient’s genetic profile, pharmacogenomics promises less medication trial and error, fewer side effects, and better overall outcomes. But does knowing a patient’s pharmacogenetic profile really improve treatment for some of the most common illnesses that we see, like depression? So far the controlled trials have been largely negative, but they’ve mainly focused on the Genesight panel. This trial tested the Genecept panel, which includes most of the genes in the Genesight panel but adds a few pharmacodynamic elements that have only preliminary evidence for use (eg, BDNF, melanocortin, and major histocompatibility complex).

This randomized controlled trial enrolled 314 adults with moderate to severe major depressive disorder who had already failed 1–3 antidepressant medications in the current depressive episode. Half the patients received treatment that was actively guided by the test, while the other half received treatment as usual. The primary outcome, change in Hamilton Depression Rating Scale score, was measured over eight weeks of treatment. The patients and researchers performing the rating scales were blinded to the treatment arm assignment, but the treating provider was not blinded.

At the end of the trial, the changes in depression scores (p = 0.53), rates of response (p = 0.17), and rates of remission (p = 0.23) were all no different between the two groups. Most of the secondary outcomes also showed no difference between the groups, including a self-report rating scale, the Clinical Global Impression-Improvement scale, and patient rating of side effects.

The authors did find that patients were more likely to remit when their medications were concordant with their test results. This finding, however, was only positive on post-hoc analysis, which means it is prone to false positives and should be interpreted with caution.

TCPR’s Take
Genecept joins the list of companies that have failed to show any benefit associated with genetic testing, even in patients who did not respond to one or more antidepressants. While this does not support the routine use of genetic testing, it doesn’t mean the tests do nothing. Consistent with earlier studies, patients fared worse when their medications were misaligned with their genetic results, but those misalignments are likely too rare to make a measurable difference.
General Psychiatry
KEYWORDS genesight genetic-testing genetics_and_psychiatry pharmacogenomics randomized-controlled-trial research research-update
    Thomas Jordan, MD.

    Methylphenidate Max Dosing

    More from this author
    www.thecarlatreport.com
    Issue Date: September 10, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Genetic Testing in Depression
    Desert Island Diagnoses
    Atomoxetine: Myths and Truths
    Overdiagnosis in Psychiatry
    Psilocybin vs Escitalopram for Depression
    Pilot Study of Ketamine vs ECT for Major Depression
    CME Post-Test - Overdiagnosis, TCPR, September 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.